Literature DB >> 23883141

Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy.

Louis R Spiegel1, Peter B Schrier, Hitesh H Shah.   

Abstract

Antiretroviral medications, specifically tenofovir, have been linked to acute tubular necrosis in humans with a suggested mechanism of direct tubular injury. Rhabdomyolysis has rarely been described in patients on highly active antiretroviral therapy (HAART). To the best of our knowledge, severe recurrent rhabdomyolysis-induced acute kidney injury (AKI) in a HIV-infected patient on two different triple antiretroviral regimens has not been reported. We present a HIV-positive patient who first developed heme pigment-induced oliguric AKI due to non-traumatic rhabdomyolysis, 5 days after initiation of triple antiretroviral therapy. Renal function normalized 2 months after discontinuation of antiretroviral therapy. Two weeks after reinitiating a different HAART regimen, our patient developed a recurrent episode of severe rhabdomyolysis-induced AKI. Both rhabdomyolysis and AKI resolved after discontinuation of the second antiretroviral regimen. First tenofovir and subsequently abacavir seem to be the likely culprits in our case. We also briefly discuss tenofovir nephrotoxicity followed by a literature review on rhabdomyolysis in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883141     DOI: 10.3109/0886022X.2013.817316

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  2 in total

Review 1.  Kidney Disease in HIV Infection.

Authors:  Gaetano Alfano; Gianni Cappelli; Francesco Fontana; Luca Di Lullo; Biagio Di Iorio; Antonio Bellasi; Giovanni Guaraldi
Journal:  J Clin Med       Date:  2019-08-19       Impact factor: 4.241

2.  Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient.

Authors:  Muhammad Saad; Fernando Casado-Castillo; Paul Kelly
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.